#1 Clinical Trials Search in Europe

Esketamine

Esketamine, a derivative of ketamine, has emerged as a promising drug in various clinical trials. These studies are investigating its potential in treating major depressive disorder, particularly treatment-resistant depression, as well as its use in anesthesia and pain management. The trials explore different administration methods, dosages, and patient populations to determine the drug’s efficacy, safety, and optimal use in medical practice.

Table of Contents

What is Esketamine?

Esketamine is a medication that belongs to a class of drugs known as N-methyl-D-aspartate (NMDA) receptor antagonists. It is derived from ketamine, a well-known anesthetic and pain reliever. Specifically, esketamine is the S-enantiomer of ketamine, which means it is a purified form of one of ketamine’s two mirror-image molecules[2]. Esketamine is approximately twice as potent as regular ketamine in terms of its analgesic (pain-relieving) effects and may have fewer side effects[1].

Esketamine is also known by its brand name Spravato® when used as a nasal spray for depression treatment[3]. Other names for esketamine include esketamine hydrochloride and JNJ-54135419[6].

Medical Uses of Esketamine

Esketamine is being studied and used for several medical purposes:

  • Treatment-Resistant Depression (TRD): Esketamine has been approved by the FDA for use in adults with TRD. It is administered as a nasal spray (Spravato®) in combination with oral antidepressants[3].
  • Pain Management: Esketamine is being investigated for treating moderate to severe pain, particularly in emergency department settings[1].
  • Anesthesia: Esketamine is used in combination with other medications for anesthesia, especially in pediatric patients undergoing procedures like laser treatments or circumcision[2][5].
  • Postoperative Pain Relief: Research is ongoing to evaluate esketamine’s effectiveness in managing pain after surgeries, such as scoliosis correction[7].
  • Chronic Postsurgical Pain Prevention: Studies are examining whether esketamine can help prevent the development of chronic pain following surgery[8].

How Esketamine is Administered

Esketamine can be administered in several ways, depending on its intended use:

  • Nasal Spray: For depression treatment, esketamine is often given as a nasal spray (Spravato®)[3].
  • Intravenous (IV) Infusion: In some studies, esketamine is administered through an IV drip, particularly for pain management or anesthesia purposes[9].
  • Patient-Controlled Analgesia (PCA): For postoperative pain management, esketamine may be combined with other medications in a PCA system, allowing patients to control their pain relief within set limits[7].

The dosage of esketamine varies depending on the condition being treated and the individual patient. It’s important to note that esketamine should only be administered under the supervision of healthcare professionals due to its potent effects and potential for side effects.

Effectiveness of Esketamine

Research suggests that esketamine can be effective in several areas:

  • Depression: Studies have shown that esketamine can rapidly improve symptoms of depression in people who haven’t responded well to other treatments[3].
  • Pain Relief: Esketamine appears to provide effective pain relief, particularly for acute pain in emergency settings[1].
  • Anesthesia: When used as part of anesthesia protocols, esketamine can help achieve desired levels of sedation with potentially fewer side effects than traditional ketamine[2].
  • Postoperative Recovery: Some research suggests that esketamine may help patients recover consciousness more quickly after anesthesia[4].

However, it’s important to note that effectiveness can vary between individuals, and more research is still needed in some areas.

Potential Side Effects

Like all medications, esketamine can cause side effects. Some potential side effects include:

  • Nausea and vomiting
  • Dizziness
  • Anxiety or agitation
  • Changes in blood pressure
  • Sedation
  • Dissociation (a feeling of being disconnected from your surroundings)

In most studies, these side effects were generally mild to moderate and resolved quickly[1]. However, due to the potential for side effects, patients receiving esketamine are typically monitored closely by healthcare professionals, especially immediately after administration.

Ongoing Research on Esketamine

Researchers continue to study esketamine to better understand its effects and potential uses. Some areas of ongoing research include:

  • Comparing the effectiveness of esketamine to ketamine for depression treatment[3].
  • Investigating the optimal dosage of esketamine for different procedures and patient groups[5].
  • Examining the long-term effects of esketamine use, particularly in preventing chronic pain after surgery[8].
  • Studying the effects of esketamine in specific patient populations, such as elderly individuals[6].

These ongoing studies aim to provide more information about how esketamine can be used safely and effectively in various medical contexts.

Aspect Details
Primary Uses Treatment of major depressive disorder, especially treatment-resistant depression; Anesthesia and pain management
Administration Methods Intranasal spray, Intravenous infusion
Key Outcome Measures Changes in depression severity (MADRS, QIDS), Global impression scales (CGI, PGI), Pharmacokinetic parameters
Patient Populations Adults with treatment-resistant depression, Elderly patients, Children (for specific procedures)
Safety Monitoring Adverse events, Vital signs, Cognitive function, Sleep quality
Potential Advantages Rapid onset of antidepressant effects, New mechanism of action (NMDA receptor antagonism)
Ongoing Research Focus Optimal dosing, Long-term efficacy and safety, Comparison with other treatments

FAQ

  • What is esketamine and how is it being used in clinical trials? Esketamine is the S-enantiomer of ketamine, a powerful anesthetic. In clinical trials, it's being studied for treating major depressive disorder, especially treatment-resistant depression, and for use in anesthesia and pain management. It's administered through various routes, including intranasal sprays and intravenous infusions.
  • How does esketamine compare to traditional antidepressants? Unlike traditional antidepressants that can take weeks to show effects, esketamine has shown rapid antidepressant effects in some trials. It works differently by targeting the NMDA receptor in the brain, potentially offering a new approach for patients who haven't responded well to other treatments.
  • What are the potential side effects of esketamine? Common side effects observed in trials include dizziness, nausea, dissociation, and increased blood pressure. Some studies are specifically monitoring for adverse events such as agitation, sedation, and potential impacts on cognitive function.
  • How is esketamine administered in these clinical trials? Administration methods vary across trials. Some use intranasal sprays, while others use intravenous infusions. The dosage and frequency of administration are being studied to determine the most effective and safe protocols.
  • Are there any special considerations for certain patient groups? Yes, some trials are focusing on specific populations such as elderly patients or children. For example, one study is comparing the pharmacokinetics and safety of esketamine in elderly versus younger adult participants to understand any age-related differences in response to the drug.

Ongoing Clinical Trials on Esketamine

  • Study on Enhanced Treatment for Schizophrenia, Depression, and Bipolar Disorder Using Esketamine, Bupropion, and Quetiapine for Patients with Initial Treatment Failure

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany Italy Spain

  • Study on the Effects of Esketamine and Remifentanil on Breathing in Healthy Volunteers

    Not recruiting

    1 1 1
    Investigated drugs:
    The Netherlands

Glossary

  • Esketamine: The S-enantiomer of ketamine, a powerful anesthetic drug. It's being studied for its potential antidepressant effects and use in anesthesia.
  • Treatment-Resistant Depression (TRD): A form of depression that doesn't respond adequately to several attempts of treatment with antidepressant medications.
  • NMDA receptor: N-methyl-D-aspartate receptor, a type of glutamate receptor in nerve cells. Esketamine acts on these receptors, which is thought to be related to its antidepressant effects.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Intranasal: A route of administering medication through the nose, allowing it to be absorbed by the nasal mucosa.
  • Intravenous (IV): A method of administering medication directly into a vein using a needle or tube.
  • Montgomery-Asberg Depression Rating Scale (MADRS): A ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders.
  • Quick Inventory of Depressive Symptomatology (QIDS): A self-report measure designed to assess the severity of depressive symptoms.
  • Clinical Global Impression (CGI): A scale used by healthcare professionals to assess the severity and improvement of mental health conditions.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Dissociation: A mental state where a person may feel disconnected from their thoughts, feelings, memories, or sense of identity.

References

  1. https://clinicaltrials.gov/study/NCT05666869
  2. https://clinicaltrials.gov/study/NCT06294639
  3. https://clinicaltrials.gov/study/NCT06713616
  4. https://clinicaltrials.gov/study/NCT06430645
  5. https://clinicaltrials.gov/study/NCT04698434
  6. https://clinicaltrials.gov/study/NCT02345148
  7. https://clinicaltrials.gov/study/NCT06062550
  8. https://clinicaltrials.gov/study/NCT06087510
  9. https://clinicaltrials.gov/study/NCT01640080